Xuanzhu Bio Pays $4.5 Million to Acquire Anti-infective for Drug-Resistant Pathogens

Xuanzhu (HK) Biopharmaceutical has agreed to acquire greater China rights to Zemdri, a novel anti-infective, from Achaogen of the US for $4.5 million. Achaogon declared bankruptcy earlier this year. Zemdri (plazomicin), a treatment for multidrug-resistant, gram-negative pathogens, is approved in the US to treat complicated urinary tract infections, though it carries a black-box safety warning. At one point, Achaogen expected Zemdri would generate $500 million in sales as a promising treatment for drug-resistant pathogens. However, the FDA did not approve Zemdri as a treatment for bloodstream infections, sending the company into bankruptcy. More details....

Share this with colleagues: